Turmocin Plus Suppresses Vascular Endothelial Growth Factor (VEGF) and Macrophage Infiltration in the Management of Perineal Wounds, Anal Fistula, Acute Anal Fissures and Haemorrhoids
Authors
-
Healing Hands Clinic, Ground Floor, Millennium Star Extension, Pune – 411001, Maharashtra. ,IN
Ashwin Porwal -
Laboratory of Tumor Biology, Angiogenesis and Nanomedicine Research, National Centre for Cell Science, Pune – 411007, Maharashtra. ,INGopal Kundu
-
R and D Center, Healing Hands and Herbs Private Limited, Pune – 411002, Maharashtra. ,INGajanan Bhagwat
-
Laboratory of Tumor Biology, Angiogenesis and Nanomedicine Research, National Centre for Cell Science, Pune – 411007, Maharashtra. ,INRamakrishna Nimma
-
School of Biotechnology, KIIT Deemed to be University, Institute of Eminence, Bhubaneswar – 751024, Odisha. ,INJayeeta Chowdhury
DOI:
https://doi.org/10.18311/jnr/2024/33298Keywords:
Anorectal Diseases, Immune Cell Infiltration, Inflammation, Turmocin Plus, Turmopain Plus CytotoxicityAbstract
Anorectal problems such as anal fistula, Crohn’s disease, haemorrhoids, and fissures are prevalent across the general population. Severe discomfort, inflammation, swelling, itching, and bleeding during defecation are common symptoms of anorectal disorders. Depending on the severity of the condition, several medical therapies or surgical procedures may be used to treat these diseases. Surgical treatments like fistulectomy and sphincterotomy or haemorrhoidectomy are highly intrusive and have a risk of recurrence. Furthermore, surgical procedures cause pain, inflammation, and perineal sores. These will lead to severe socio-economic ramifications in the patient’s life. Therefore, treatment options that aid in the reduction of inflammation, pain, and perineal wounds are critical for anorectal disease management. Herbal formulations that comprise turmeric (Curcuma longa) extract have anti-inflammatory, pain-relieving, and wound-healing properties. The purpose of the current study was to elucidate the effect of Turmocin Plus on the infiltration of inflammatory cells and the expression of pro-angiogenic factors in anorectal and lower gastrointestinal disorders. MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) and wound migration assays were performed to determine the results of Turmocin Plus on the viability and migration of inflammatory cells. The effect of Turmocin Plus on pro-angiogenic factors was determined using Western blot analysis and immunofluorescence. Further, we validate our in vitro findings in human fistula specimens using IHC. The investigation showed that Turmocin Plus inhibits immunological (RAW 264.7) cell migration while maintaining their viability. Inflammation and increased levels of Vascular Endothelial Growth Factor (VEGF) were observed in Inflammatory Bowel Disease (IBD), fistula, fissures, and higher-grade haemorrhoids. However, Turmocin Plus suppresses the VEGF expression in macrophages (RAW 264.7) cells. Furthermore, compared to untreated human fistula tissues, decreased expression of VEGF was observed in Turmocin Plus treated patient samples, validating the in vitro findings. Our study suggests that Turmocin Plus is a potent therapeutic formulation in treating fistula, perineal wounds, and Crohn’s disease.
Downloads
Metrics
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Ashwin Porwal, Gopal Kundu, Gajanan Bhagwat, Ramakrishna Nimma, Jayeeta Chowdhury (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Accepted 2023-11-27
Published 2024-02-01
References
Foxx-Orenstein AE, Umar SB, Crowell MD. Common anorectal disorders. Gastroenterol Hepatol (N Y). 2014; 10(5):294-301.
Hollingshead JR, Phillips RK. Hemorrhoids: modern diagnosis and treatment. Postgrad Med J. 2016; 92(1083): 4-8. https://doi.org/10.1136/postgradmedj-2015-133328 DOI: https://doi.org/10.1136/postgradmedj-2015-133328
Mott T, Latimer K, Edwards C. Hemorrhoids: diagnosis and treatment options. Am Fam Physician. 2018; 97(3):172-9.
Clinical practice committee, American gastroenterological association. American gastroenterological association medical position statement: Diagnosis and treatment of hemorrhoids. Gastroenterology. 2004; 126(5):1461-2.
Sun Z, Migaly J. Review of Hemorrhoid disease: Presentation and management. Clin Colon Rectal Surg. 2016; 29(1):22-9. https://doi.org/10.1055/s-0035-1568144 DOI: https://doi.org/10.1055/s-0035-1568144
Guindic LC. Treatment of uncomplicated hemorrhoids with a Hemor-Rite® cryotherapy device: a randomized, prospective, comparative study. J Pain Res. 2014; 7:57-63. https://doi.org/10.2147/JPR.S42872 DOI: https://doi.org/10.2147/JPR.S42872
Riss S, Weiser FA, Schwameis K, Riss T, Mittlböck M, Steiner G, et al. The prevalence of hemorrhoids in adults. Int J Colorectal Dis. 2012; 27(2):215-20. https://doi.org/10.1007/ s00384-011-1316-3 DOI: https://doi.org/10.1007/s00384-011-1316-3
Chong PS, Bartolo DC. Hemorrhoids and fissure in ano. Gastroenterol Clin North Am. 2008; 37(3):627-44. https:// doi.org/10.1016/j.gtc.2008.07.001 DOI: https://doi.org/10.1016/j.gtc.2008.07.001
Thomson WH. The nature of hemorrhoids. Br J Surg. 1975; 62(7):542-52. https://doi.org/10.1002/bjs.1800620710 DOI: https://doi.org/10.1002/bjs.1800620710
Shrivastava L, da Silva Borges G, Shrivastava R. Clinical efficacy of a dual action, topical anti-edematous and anti-inflammatory device for the treatment of external hemorrhoids. Clin Exp Pharmacol Physiol. 2018; 8(1):1000246. https://doi.org/10.4172/2161-1459.1000246 DOI: https://doi.org/10.4172/2161-1459.1000246
Tafti LD, Shariatpanahi SM, Damghani MM, Javadi B. Traditional Persian topical medications for gastrointestinal diseases. Iran J Basic Med Sci. 2017; 20(3):222-41. https:// doi.org/10.22038/ijbms.2017.8349
Shrivastava R. Naturveda, Non-solid composition for local application. U.S. Patent. 2005; p. 6, 964, 783.
Chung YC, Hou YC, Pan AC. Endoglin (CD105) expression in the development of haemorrhoids. Eur J Clin Invest. 2004; 34(2):107-12. https://doi.org/10.1111/j.1365-2362. 2004.01305.x DOI: https://doi.org/10.1111/j.1365-2362.2004.01305.x
Han W, Wang ZJ, Zhao B, Yang XQ, Wang D, Wang JP, et al. Pathologic change of elastic fibers with a difference in microvessel density and expression of angiogenesis-related proteins in internal hemorrhoid tissues. Zhonghua Wei Chang Wai Ke Za Zhi. 2005; 8(1):56-9.
Higuero T. Update on the management of anal fissure. J Visc Surg. 2015; 152(2):S37-43. https://doi.org/10.1016/ j.jviscsurg.2014.07.007 DOI: https://doi.org/10.1016/j.jviscsurg.2014.07.007
Villalba H, Villalba S, Abbas MA. Anal fissure: A common cause of anal pain. Perm J. 2007; 11(4):62-5. https://doi. org/10.7812/TPP/07-072 DOI: https://doi.org/10.7812/TPP/07-072
Tranqui P, Trottier DC, Victor C, Freeman JB. Nonsurgical treatment of chronic anal fissure: Nitroglycerin and dilatation versus nifedipine and botulinum toxin. Can J Surg. 2006; 49(1):41-5.
Simpson JA, Banerjea A, Scholefield JH. Management of anal fistula. British Medical Journal. 2012; 345:e6705. https://doi.org/10.1136/bmj.e6705 DOI: https://doi.org/10.1136/bmj.e6705
Vogel JD, Johnson EK, Morris AM, Paquette IM, Saclarides TJ, Feingold DL, et al. Clinical practice guideline for the management of anorectal abscess, fistula-in-ano, and rectovaginal fistula. Dis Colon Rectum. 2016; 59(12): 1117-33. https://doi.org/10.1097/DCR.0000000000000733 DOI: https://doi.org/10.1097/DCR.0000000000000733
Cirocchi R, Trastulli S, Morelli U, Desiderio J, Boselli C, Parisi A, et al. The treatment of anal fistulas with biologically derived products: Is innovation better than conventional surgical treatment? An update. Tech Coloproctol. 2013; 17:259-73. https://doi.org/10.1007/s10151-012-0948-9 DOI: https://doi.org/10.1007/s10151-012-0948-9
Parks AG. Pathogenesis and treatment of fistula-in-ano. British Medical Journal. 1961; 1(5224):463-9. https://doi. org/10.1136/bmj.1.5224.463 DOI: https://doi.org/10.1136/bmj.1.5224.463
Gardner IH, Siddharthan RV, Tsikitis VL. Benign anorectal disease: Hemorrhoids, fissures, and fistulas. Ann Gastroenterol. 2020; 33(1):9-18. https://doi.org/10.20524/ aog.2019.0438
Whiteford MH. Perianal abscess/fistula disease. Clin Colon Rectal Surg. 2007; 20(2):102-9. https://doi.org/ 10.1055/s-2007-977488 DOI: https://doi.org/10.1055/s-2007-977488
Chang CC, Lan YT, Jiang JK, Chang SC, Yang SH, Lin CC, et al. Risk factors for delayed perineal wound healing and its impact on prolonged hospital stay after abdominoperineal resection. World J Surg Oncol. 2019; 17(1):226. https://doi. org/10.1186/s12957-019-1768-4 DOI: https://doi.org/10.1186/s12957-019-1768-4
Rakinic J, Poola VP. Hemorrhoids and fistulas: New solutions to old problems. Curr Probl Surg. 2014; 51(3): 98-137. https://doi.org/10.1067/j.cpsurg.2013.11.002 DOI: https://doi.org/10.1067/j.cpsurg.2013.11.002
Hashempur MH, Khademi F, Rahmanifard M, Zarshenas MM. An evidence-based study on medicinal plants for hemorrhoids in medieval Persia. J Evid Based Complementary Altern Med. 2017; 22(4):969–81. https:// doi.org/10.1177/2156587216688597 DOI: https://doi.org/10.1177/2156587216688597
Bhagwat G, Kamble P, Porwal A, Barge V. To evaluate accelerated stability study of a polyherbal formulation- Turmocin Plus tablet. Int J Pharm Res. 2021; 13(3):946-53. https://doi.org/10.31838/ijpr/2021.13.03.146 DOI: https://doi.org/10.31838/ijpr/2021.13.03.146
Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 2008; 68(1):152-61. https://doi. org/10.1158/0008-5472.CAN-07-2126 DOI: https://doi.org/10.1158/0008-5472.CAN-07-2126
Kumar D, Haldar S, Gorain M, Kumar S, Mulani FA, Yadav AS, et al. Epoxyazadiradione suppresses breast tumor growth through mitochondrial depolarization and caspasedependent apoptosis by targeting PI3K/Akt pathway. BMC Cancer. 2018; 18(1):52. https://doi.org/10.1186/s12885- 017-3876-2 DOI: https://doi.org/10.1186/s12885-017-3876-2
Segre D, Dal Corso HM, Landra M, Giuffrida MC. Management of the unhealed perineal wound in: Inflammatory bowel disease and familial adenomatous polyposis. Delaini GG (ed). Springer, Milano. 2006. p. 463- 72. https://doi.org/10.1007/88-470-0434-9_49 DOI: https://doi.org/10.1007/88-470-0434-9_49
Chen S, Yu Q. A new theory on the cause of anal fissure– impaction theory. J Coloproctol (Rio J). 2020; 40(4):321-5. https://doi.org/10.1016/j.jcol.2020.06.006 DOI: https://doi.org/10.1016/j.jcol.2020.06.006
Marzo M, Felice C, Pugliese D, Andrisani G, Mocci G, Armuzzi A, et al. Management of perianal fistulas in Crohn’s disease: An up-to-date review. World J Gastroenterol. 2015; 21(5):1394-403. https://doi.org/10.3748/wjg.v21.i5.1394 DOI: https://doi.org/10.3748/wjg.v21.i5.1394
Barnhoorn MC, Hakuno SK, Bruckner RS, Rogler G, Hawinkels LJAC, Scharl M. Stromal cells in the pathogenesis of inflammatory bowel disease. J Crohn’s Colitis. 2020; 14(7):995-1009. https://doi.org/10.1093/ecco-jcc/jjaa009 DOI: https://doi.org/10.1093/ecco-jcc/jjaa009
van Onkelen RS, Gosselink MP, van Meurs M, Melief MJ, Schouten WR, Laman JD. Proinflammatory cytokines in cryptoglandular anal fistulas. Tech Coloproctol. 2016; 20(9):619-25. https://doi.org/10.1007/s10151-016-1494-7 DOI: https://doi.org/10.1007/s10151-016-1494-7
Landén NX, Li D, Ståhle M. Transition from inflammation to proliferation: A critical step during wound healing. Cell Mol Life Sci. 2016; 73(20):3861-85. https://doi.org/10.1007/ s00018-016-2268-0 DOI: https://doi.org/10.1007/s00018-016-2268-0
Bertone AL. Principles of wound healing. Vet Clin North Am Equine Pract. 1989; 5(3):449-63. https://doi. org/10.1016/S0749-0739(17)30568-0 DOI: https://doi.org/10.1016/S0749-0739(17)30568-0
Scaldaferri F, Vetrano S, Sans M, Arena V, Straface G, Stigliano E, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology. 2009; 136(2):585-95.e5. https://doi.org/ 10.1053/j.gastro.2008.09.064 DOI: https://doi.org/10.1053/j.gastro.2008.09.064
Wojdasiewicz P, Poniatowski ŁA, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm. 2014; 2014:561459. https://doi.org/10.1155/2014/561459 DOI: https://doi.org/10.1155/2014/561459
Haddow JB, Musbahi O, MacDonald TT, Knowles CH. Comparison of cytokine and phosphoprotein profiles in idiopathic and Crohn’s disease-related perianal fistula. World J Gastrointest Pathophysiol. 2019; 10(4):42-53. https://doi.org/10.4291/wjgp.v10.i4.42 DOI: https://doi.org/10.4291/wjgp.v10.i4.42
Danese S, Sans M, de la Motte C, Graziani C, West G, Phillips MH, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology. 2006; 130(7):2060-73. https://doi.org/ 10.1053/j.gastro.2006.03.054 DOI: https://doi.org/10.1053/j.gastro.2006.03.054
Lund JN, Scholefield JH. A randomized, prospective, double-blind, placebo-controlled trial of glyceryl trinitrate ointment in the treatment of anal fissure. Lancet. 1997; 349(9044):11-4. https://doi.org/10.1016/ S0140-6736(96)06090-4 DOI: https://doi.org/10.1016/S0140-6736(96)06090-4
Brisinda G, Cadeddu F, Brandara F, Marniga G, Maria G. Randomized clinical trial comparing botulinum toxin injections with 0.2 percent nitroglycerin ointment for chronic anal fissure. Br J Surg. 2007; 94(2):162-7. https:// doi.org/10.1002/bjs.5514 DOI: https://doi.org/10.1002/bjs.5514
Sileri P, Stolfi VM, Franceschilli L, Grande M, Di Giorgio A, D’Ugo S, et al. Conservative and surgical treatment of chronic anal fissure: Prospective longer term results. J Gastrointest Surg. 2010; 13:47. https://doi.org/10.1007/ s11605-010-1154-6
Lohsiriwat V. Treatment of hemorrhoids: A coloproctologist’s view. World J Gastroenterol. 2015; 21(31):9245-52. https:// doi.org/10.3748/wjg.v21.i31.9245 DOI: https://doi.org/10.3748/wjg.v21.i31.9245
Nyam DC, Pemberton JH. Long-term results of lateral internal sphincterotomy for chronic anal fissure with particular reference to incidence of fecal incontinence. Dis Colon Rectum. 1999; 42(10):1306-10. https://doi.org/ 10.1007/BF02234220 DOI: https://doi.org/10.1007/BF02234220
Sheikh P, Baakza A. Management of fistula-in-ano—The current evidence. Indian J Surg. 2014; 76(6):482-6. https:// doi.org/10.1007/s12262-014-1150-2 DOI: https://doi.org/10.1007/s12262-014-1150-2
Emile SH. Recurrent anal fistulas: When, why, and how to manage? World J Clin Cases. 2020; 8(9):1586-91. https:// doi.org/10.12998/wjcc.v8.i9.1586 DOI: https://doi.org/10.12998/wjcc.v8.i9.1586
Guo S, Dipietro LA. Factors affecting wound healing. J Dent Res. 2010; 89(3):219-29. https://doi.org/ 10.1177/0022034509359125 DOI: https://doi.org/10.1177/0022034509359125
Kamrava A, Mahmoud NN. Prevention and management of nonhealing perineal wounds. Clin Colon Rectal Surg. 2013; 26(2):106-11. https://doi.org/10.1055/s-0033-1348049 DOI: https://doi.org/10.1055/s-0033-1348049
Lohsiriwat V. Hemorrhoids: From basic pathophysiology to clinical management. World J Gastroenterol. 2012; 18(17):2009-17. https://doi.org/10.3748/wjg.v18.i17.2009 DOI: https://doi.org/10.3748/wjg.v18.i17.2009
Porwal A, Kundu GC, Bhagwat G, Butti R. Herbal medicine AnoSpray suppresses proinflammatory cytokines COX-2 and RANTES in the management of hemorrhoids, acute anal fissures and perineal wounds. Exp Ther Med. 2022; 23(1):86. https://doi.org/10.3892/etm.2021.11009 DOI: https://doi.org/10.3892/etm.2021.11009
Porwal A, Kundu GC, Bhagwat G, Butti R. Polyherbal formulation Anoac-H suppresses the expression of RANTES and VEGF for the management of bleeding hemorrhoids and fistula. Mol Med Rep. 2021; 24(4):736. https://doi.org/10.3892/mmr.2021.12376 DOI: https://doi.org/10.3892/mmr.2021.12376
Porwal A, Gandhi P, Kulkarni D. An open label, randomized, comparative, parallel group, single center study to evaluate safety and efficacy of Ano spray in a comparison with betadine solution application in acute perineum wounds. Ayushdhara. 2017; 4(6):1409-12. https://ayushdhara.in/ index.php/ayushdhara/article/view/346
Porwal A, Gandhi P, Kulkarni D. Effectiveness of curcumin rich formulation for overall recovery time after perianal surgery. World J Pharm Pharm Sci. 2019; 8(10): 579-86.
Ferrante M, Pierik M, Henckaerts L, Joossens M, Claes K, Van Schuerbeek N, et al. The role of Vascular Endothelial Growth Factor (VEGF) in inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12(9):870-8. https://doi.org/ 10.1097/01.mib.0000235095.01608.10 DOI: https://doi.org/10.1097/01.mib.0000235095.01608.10
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9(6):669-76. https://doi. org/10.1038/nm0603-669 DOI: https://doi.org/10.1038/nm0603-669
Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marmé D. Migration of human monocytes in response to Vascular Endothelial Growth Factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996; 87(8):3336-43. https:// doi.org/10.1182/blood.V87.8.3336.bloodjournal8783336 DOI: https://doi.org/10.1182/blood.V87.8.3336.bloodjournal8783336
Majno G. Chronic inflammation: Links with angiogenesis and wound healing. Am J Pathol. 1998; 153(4):1035-9. https://doi.org/10.1016/S0002-9440(10)65648-9 59. Bagli E, Xagorari A, Papetropoulos A, Murphy C, Fotsis T. Angiogenesis in inflammation. Autoimmun Rev. 2004; 3(1):S26. DOI: https://doi.org/10.1016/S0002-9440(10)65648-9
Szekanecz Z, Koch AE. Vascular endothelium and immune responses: Implications for inflammation and angiogenesis. Rheum Dis Clin North Am. 2004; 30(1):97-114. https://doi. org/10.1016/S0889-857X(03)00116-9 DOI: https://doi.org/10.1016/S0889-857X(03)00116-9
Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. Federation of American Societies for Experimental Biology Journal. 1997; 11(6):457-65. https:// doi.org/10.1096/fasebj.11.6.9194526 DOI: https://doi.org/10.1096/fasebj.11.6.9194526
Urošević M, Nikolić L, Gajić I, Nikolić V, Dinić A, Miljković V. Curcumin: Biological Activities and Modern Pharmaceutical Forms. Antibiotics (Basel). 2022; 11(2):135. https://doi.org/10.3390/antibiotics11020135 DOI: https://doi.org/10.3390/antibiotics11020135
Takooree H, Aumeeruddy MZ, Rengasamy KRR, Venugopala KN, Jeewon R, Zengin G, et al. A systematic review on black pepper (Piper nigrum L.): From folk uses to pharmacological applications. Crit Rev Food Sci Nutr. 2019; 59(1):S210-43. https://doi.org/10.1080/10408398. 2019.1565489. DOI: https://doi.org/10.1080/10408398.2019.1565489
0.35
24
0.161